| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Orcinol glucoside modulates the Wnt/β-catenin signaling pathway. It facilitates the shift of mesenchymal stem cell fate to osteoblast and prevents adipogenesis via Wnt/β-catenin signaling. The compound also produces antidepressant effects by downregulating HPA axis hyperactivity and increasing BDNF expression and ERK1/2 phosphorylation in the hippocampus.
|
|---|---|
| ln Vitro |
In vitro, orcinol glucoside displays concentration-dependent DPPH radical scavenging activity with an IC₅₀ of 900 µg/mL and 69.3% activity at 2 mg/mL. It facilitates the differentiation of mesenchymal stem cells toward osteoblasts and prevents adipogenesis through Wnt/β-catenin signaling. The compound also demonstrates antioxidant and anxiolytic activities without sedative effects.
|
| ln Vivo |
In vivo, orcinol glucoside improves depressive behavior in chronic unpredictable mild stress (CUMS) rats. It produces antidepressant effects by blocking the behavioral and neuronal deficits caused by chronic stress. The compound modulates bone metabolism by promoting osteoblast differentiation and inhibiting osteoclast activity, suggesting potential in osteoporosis research.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, orcinol glucoside can be evaluated for its antioxidant activity using cell-free DPPH radical scavenging assays. The compound is incubated with DPPH radical solution, and the decrease in absorbance at 517 nm is measured. The scavenging activity is calculated as a percentage, and IC₅₀ values are determined from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, orcinol glucoside is typically tested on mesenchymal stem cells (MSCs) or neuronal cell lines. MSCs are treated with the compound at various concentrations (typically 1-100 μM) and assessed for osteogenic differentiation using alkaline phosphatase staining, alizarin red staining, and expression of osteogenic markers by qPCR or Western blotting. Neuronal cells can be used to evaluate neuroprotective effects.
|
| Animal Protocol |
For in vivo animal experiments, orcinol glucoside is typically administered orally to rodent models of depression (CUMS model) or osteoporosis (ovariectomized mice). Behavioral tests such as the forced swim test, sucrose preference test, and open field test are performed to evaluate antidepressant effects. Bone mineral density and microarchitecture are assessed by micro-CT. Hippocampal BDNF expression and ERK1/2 phosphorylation are measured by Western blotting.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for orcinol glucoside are limited. As a glycoside natural product, it is expected to have moderate oral bioavailability and may undergo metabolism in the gastrointestinal tract. The compound's molecular weight and formula are well-characterized. Standard pharmacokinetic studies would involve oral administration to rodents followed by plasma collection and LC-MS/MS analysis to determine PK parameters.
|
| Toxicity/Toxicokinetics |
Toxicological data for orcinol glucoside are limited. As a natural product isolate from Curculigo orchioides, a plant used in traditional medicine, it is generally considered to have low toxicity at pharmacological doses. However, comprehensive toxicological studies have not been reported. The compound is classified as a research-grade reagent.
|
| References |
|
| Additional Infomation |
Resorcinol glucoside is a glycoside. It has been reported to be found in helichrysum, curculigo, and ranunculus capitulata, and relevant data exist.
Orcinol glucoside is a research-use only compound and has not been approved for clinical applications. It is also known as Sakakin and苔黑酚葡萄糖苷 in Chinese. The compound is isolated from the rhizomes of Curculigo orchioides Gaertn. Its molecular formula is well-characterized, and it is available from various research chemical suppliers. |
| Molecular Formula |
C13H18O7
|
|---|---|
| Molecular Weight |
286.2778
|
| Exact Mass |
286.105
|
| CAS # |
21082-33-7
|
| PubChem CID |
12315192
|
| Appearance |
White to off-white solid
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
570.6±50.0 °C at 760 mmHg
|
| Melting Point |
132 °C
|
| Flash Point |
298.9±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.637
|
| LogP |
-0.77
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
313
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1[C@]([H])([C@@]([H])([C@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[H])O[H])O[H])O[H])OC1C([H])=C(C([H])=C(C([H])([H])[H])C=1[H])O[H]
|
| InChi Key |
YTXIGTCAQNODGD-HENWMNBSSA-N
|
| InChi Code |
InChI=1S/C13H18O7/c1-6-2-7(15)4-8(3-6)19-13-12(18)11(17)10(16)9(5-14)20-13/h2-4,9-18H,5H2,1H3/t9-,10-,11+,12-,13?/m1/s1
|
| Chemical Name |
(2R,3S,4S,5R)-2-(hydroxymethyl)-6-(3-hydroxy-5-methylphenoxy)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~436.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4931 mL | 17.4654 mL | 34.9308 mL | |
| 5 mM | 0.6986 mL | 3.4931 mL | 6.9862 mL | |
| 10 mM | 0.3493 mL | 1.7465 mL | 3.4931 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
